Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor

Annals of Oncology

Volumn 19, Issue 8, 2008, Pages 1435-1441

  de la Motte Rouge, T ^a   Pautier, P ^a   Duvillard, P ^a   Rey, A ^a   Morice, P ^a   Haie Meder, C ^a   Kerbrat, P ^b   Culine, S ^c   Troalen, F ^a   Lhomme C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

Alpha fetoprotein; BEP; Endodermal sinus tumor; Fertility; Malignant ovarian germ cell tumor

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONCEPTION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMALE FERTILITY; FEMALE GENITAL SYSTEM; FOLLOW UP; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONITIS; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPRODUCTION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; YOLK SAC TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ENDODERMAL SINUS TUMOR; ETOPOSIDE; FEMALE; FERTILITY; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 48749126166     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn162     Document Type: Article

References (32)

1. Smith HO, Berwick M, Verschraegen CF et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006; 107(5): 1075-1085.
2. Teilum G. Endodermal sinus tumors of the ovary and testis. Comparative morphogenesis of the so-called mesoephroma ovarii (Schiller) and extraembryonic (yolk sac-allantoic) structures of the rat's placenta. Cancer 1959; 12: 1092-1105.
3. Talerman A, Haije WG, Baggerman L. Serum alphafetoprotein (AFP) in diagnosis and management of endodermal sinus (yolk sac) tumor and mixed germ cell tumor of the ovary. Cancer 1978; 41(1): 272-278.
4. Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: A clinical and pathologic analysis of 71 cases. Cancer 1976; 38(6): 2404-2419.
5. Dallenbach P, Bonnefoi H, Pelte MF, Vlastos G. Yolk sac tumours of the ovary: An update. Eur J Surg Oncol 2006; 32(10): 1063-1075.
6. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 2007; 25(20): 2938-2943.
7. Gershenson DM, Morris M, Cangir A et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990; 8(4): 715-720.
8. Williams S; Blessing JA, Liao SY et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group. J Clin Oncol 1994; 12(4): 701-706.
9. Schneider DT, Calaminus G, Koch S et al. Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols. Pediatr Blood Cancer 2004; 42(2): 169-175.
10. WHO. Pathology and Genetics at Tumours of the Breast and Female Genital Tract. Lyon: WHO, IARC press, 2003.
11. Benedet JL, Bender H, Joneslli H, Ngan HY, Pecoreill S. FIGO staging classifications and clinical pracfice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Onoology. Int J Gynaecol Obstet 2000; 70(2): 209-262.
12. Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23(27): 6549-6555.
13. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316(23): 1435-1440.
15. Gershenson DM, Del Junco G, Herson J, Rutledge FN. Endodermal sinus tumor of the ovary: The M.D. Anderson experience. Obstet Gynecol 1983; 61(2): 194-202.
16. Nawa A, Obata N, Kikkawa F et al. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol 2001; 184(6): 1182-1188.
17. Ayhan A, Taskiran C, Bozdag G et al. Endodermal sinus tumor of the ovary: The Hacettepe University experience. Eur J Obstet Gynecol Reprod Biol 2005; 123(2): 230-234.
18. Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15(9): 1377-1399.
19. de Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15(5): 1837-1843.
20. Sagstuen H, Aass N, Fossa SD et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23(22): 4980-4990.
21. Culine S, Lhomme C, Kattan J et al. Cisplatin-based chemotherapy in the management of germ cell tumors of the ovary: The Institut Gustave Roussy Experience. Gynecol Oncol 1997; 64(1): 160-165.
22. Mitchell PL, Al-Nasiri N, A'Hern R et al. Treatment of nondysgerminomatous ovarian germ cell tumors: An analysis of 69 cases. Cancer 1999; 85(10): 2232-2244.
23. Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000; 89(2): 391-398.
24. Zanetta G, Bonazzi C, Cantu M et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001; 19(4): 1015-1020.
25. Brewer M, Gershenson DM, Herzog CE et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999; 17(9): 2670-2675.
26. Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 1988; 6(2): 270-275.
27. Tangir J, Zeltenman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003; 101(2): 251-257.
28. Gershenson DM, Miller AM, Champion VL et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25(19): 2792-2797.
29. Dark GG, Bower M, Newlands ES et al. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 1997; 15(2): 620-624.
30. Einhorn LH, Williams SO, Chamness A et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357(4): 340-348.
31. Jeyakumar A, Chalas E, Hindenburg A. Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor. Gynecol Oncol 2001; 82(3): 578-580.
32. Zagame L, Pautier P, Duvillard P et al. Growing teratoma syndrome after ovarian germ cell tumors. Obstet Gynecol 2006; 108(3 Pt 1): 509-514.